What AI stock is Cathie Wood buying?

Cathie Wood Bets Big on Tempus AI—Here’s Why

When Cathie Wood, the outspoken CEO of ARK Invest, buys into a stock, investors tend to take notice. In early 2026, she added a new name to her high-conviction portfolio: Tempus AI. Since its IPO in June 2024, Wood’s funds have been steadily accumulating shares, signaling strong confidence in the company’s long-term potential.

Tempus AI isn’t just another artificial intelligence play—it’s at the intersection of healthcare and cutting-edge data science. The company specializes in AI-powered diagnostic tools that help oncologists and other specialists make more precise, personalized treatment decisions. By analyzing vast amounts of clinical and molecular data, Tempus enables faster, more accurate diagnoses, particularly in complex cases like cancer.

But the real value, at least from an investor’s standpoint, lies beyond diagnostics. Tempus also anonymizes and aggregates the data from its tests, selling it to pharmaceutical companies for use in drug discovery and clinical trials. This dual-revenue model—providing tools to doctors while fueling R&D for drugmakers—creates a compelling data moat that few competitors can match.

Wood has always favored companies that combine disruptive technology with scalable data networks, and Tempus AI fits the profile. Her aggressive buying post-IPO suggests she sees it as a foundational player in the future of precision medicine. In a market where AI hype often outpaces reality, Tempus stands out by delivering tangible clinical impact—and revenue.

While the stock has seen typical post-IPO volatility, Wood’s backing adds credibility. For investors watching the ARK playbook, Tempus AI may be one to watch as AI continues to reshape healthcare from the ground up.